STING Monoclonal Antibody (Clone

Confirm delete?

STING Monoclonal Antibody (Clone 2C8)

Zoom

Cat No: 17856

Stimulator of Interferon Genes (STING) is a component of the innate immune response. STING binds to cyclic dinucleotides, which are bacterial second messengers.{24607} Recognition of cyclic-di-GMP (c-di-GMP), c-di-AMP, or c-GMP-AMP leads to activation...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

cdiGMP cdiAMP cGMPAMP NF?B TMEM-173 IRF-3

Product Overview:
Stimulator of Interferon Genes (STING) is a component of the innate immune response. STING binds to cyclic dinucleotides, which are bacterial second messengers.{24607} Recognition of cyclic-di-GMP (c-di-GMP), c-di-AMP, or c-GMP-AMP leads to activation of NF-κB and transcription of immunomodulatory genes, including type I interferon (IFN).{22400,22401,24611} Loss of STING regulation contributes to autoimmune disorders through increased IFN activity.{24608} The gene for STING is mutated in the mouse strain Goldenticket, which consequently lacks a type I IFN response to Listeria infection.{24612} Activation of STING by the flavonoid 5,6-dimethylxanthenone-4-acetic acid (DMXAA; Item No. 14617) has been shown to kill solid tumors in mice, but the binding site of DMXAA is not conserved in human STING.{24610,24609} Cayman’s STING Monoclonal Antibody (Clone 2C8) can be used for ELISA, immunohistochemistry, and Western blot applications. The antibody recognizes STING at 42 kDa from human samples.

Size	100 µg
Shipping	dry ice
Host	Mouse
Antigen	Human recombinant STING protein AA 139-379
Clone	2C8
Isotype	IgG1
Application(s)	ELISA, IHC, and WB
Formulation	100 µg of protein G-purified monoclonal antibody
Custom Code	3822.19
UNSPSC code	12352203

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.